Status:
RECRUITING
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
Lead Sponsor:
MiraKind
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obta...
Detailed Description
The investigators have identified germ-line microRNA binding site mutations that predict an increased risk of cancer, endometriosis and associated infertility, and unique tumor biology and response to...
Eligibility Criteria
Inclusion
- Personal or family history of cancer
- Personal history of endometriosis, or autoimmunity
Exclusion
- Younger than 18
- Non-english speaking and unable to understand and sign the consent
Key Trial Info
Start Date :
September 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2035
Estimated Enrollment :
15000 Patients enrolled
Trial Details
Trial ID
NCT02253251
Start Date
September 1 2014
End Date
September 1 2035
Last Update
January 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MiraKind
Los Angeles, California, United States, 90025